BR0209145A - Vacina contra varìola - Google Patents

Vacina contra varìola

Info

Publication number
BR0209145A
BR0209145A BR0209145-3A BR0209145A BR0209145A BR 0209145 A BR0209145 A BR 0209145A BR 0209145 A BR0209145 A BR 0209145A BR 0209145 A BR0209145 A BR 0209145A
Authority
BR
Brazil
Prior art keywords
vaccine
smallpox vaccine
smallpox
processes
vaccines
Prior art date
Application number
BR0209145-3A
Other languages
English (en)
Inventor
Richard A Weltzin
Thomas P Monath
Original Assignee
Acambis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acambis Inc filed Critical Acambis Inc
Publication of BR0209145A publication Critical patent/BR0209145A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • A61K39/285Vaccinia virus or variola virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"VACINA CONTRA VARìOLA". A invenção refere-se a vacina de vírus da varíola atenuada que pode ser usada nos processos para impedir ou tratar varíola em pacientes, bem como processos para obtenção de tais vacinas.
BR0209145-3A 2001-04-23 2002-04-23 Vacina contra varìola BR0209145A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/840,751 US6723325B1 (en) 2001-04-23 2001-04-23 Smallpox vaccine
PCT/US2002/012616 WO2002085411A1 (en) 2001-04-23 2002-04-23 Smallpox vaccine

Publications (1)

Publication Number Publication Date
BR0209145A true BR0209145A (pt) 2005-04-19

Family

ID=25283120

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209145-3A BR0209145A (pt) 2001-04-23 2002-04-23 Vacina contra varìola

Country Status (20)

Country Link
US (2) US6723325B1 (pt)
EP (1) EP1381389B1 (pt)
JP (1) JP4397591B2 (pt)
KR (1) KR20040063083A (pt)
CN (1) CN1527722A (pt)
AU (1) AU2002258910B2 (pt)
BR (1) BR0209145A (pt)
CA (1) CA2444747C (pt)
CZ (1) CZ305819B6 (pt)
EA (1) EA007656B1 (pt)
ES (1) ES2546612T3 (pt)
HK (1) HK1062804A1 (pt)
HU (1) HU228401B1 (pt)
IL (2) IL158549A0 (pt)
MA (1) MA26270A1 (pt)
MX (1) MXPA03009711A (pt)
NZ (1) NZ529265A (pt)
PL (1) PL212117B1 (pt)
WO (1) WO2002085411A1 (pt)
ZA (1) ZA200309084B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723325B1 (en) * 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine
US7645456B2 (en) * 2001-04-23 2010-01-12 Sanofi Pasteur Biologics Co. Vaccinia virus strains
WO2006113927A2 (en) * 2005-04-20 2006-10-26 University Of Washington Immunogenic vaccinia peptides and methods of using same
TWI417113B (zh) 2006-11-07 2013-12-01 Acambis Inc 以凍乾法穩定疫苗
KR100859345B1 (ko) * 2006-12-12 2008-09-19 씨제이제일제당 (주) 세포배양에 의해 두창 백신을 생산하는 방법 및 그에 의해생산된 두창 백신
EA201301173A1 (ru) 2011-04-15 2015-08-31 Дженелюкс Корпорейшн Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
RU2496149C1 (ru) * 2012-06-19 2013-10-20 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") Способ оценки противооспенной активности лечебно-профилактических препаратов
US11345896B2 (en) 2016-11-02 2022-05-31 David Evans Synthetic chimeric poxviruses
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
EP3876951A1 (en) 2018-11-06 2021-09-15 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315914A (en) * 1980-04-04 1982-02-16 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof
JPS60202827A (ja) 1984-03-28 1985-10-14 Chibaken 弱毒痘そうワクチン株
US5614193A (en) * 1991-11-14 1997-03-25 The United States Of America As Represented By The Secretary Of The Army Hantavirus vaccine
US5656465A (en) * 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US6723325B1 (en) * 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine

Also Published As

Publication number Publication date
CA2444747C (en) 2018-04-17
EP1381389A4 (en) 2004-07-28
WO2002085411A1 (en) 2002-10-31
IL158549A0 (en) 2004-05-12
HK1062804A1 (en) 2004-11-26
MXPA03009711A (es) 2005-03-07
AU2002258910B2 (en) 2007-10-25
CN1527722A (zh) 2004-09-08
MA26270A1 (fr) 2004-09-01
EA007656B1 (ru) 2006-12-29
HUP0303878A3 (en) 2010-01-28
KR20040063083A (ko) 2004-07-12
CZ20033184A3 (cs) 2004-04-14
CZ305819B6 (cs) 2016-03-30
US6723325B1 (en) 2004-04-20
JP4397591B2 (ja) 2010-01-13
PL373958A1 (en) 2005-09-19
HUP0303878A2 (hu) 2004-03-01
CA2444747A1 (en) 2002-10-31
US20060153873A1 (en) 2006-07-13
EA200301151A1 (ru) 2004-10-28
ZA200309084B (en) 2005-01-26
US7115270B2 (en) 2006-10-03
NZ529265A (en) 2006-04-28
JP2005503126A (ja) 2005-02-03
ES2546612T3 (es) 2015-09-25
HU228401B1 (en) 2013-03-28
PL212117B1 (pl) 2012-08-31
EP1381389B1 (en) 2015-08-26
EP1381389A1 (en) 2004-01-21
IL158549A (en) 2009-07-20

Similar Documents

Publication Publication Date Title
AP2000001942A0 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections.
PL375621A1 (en) Pharmaceutical compositions comprising flavonoids and menthol
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
ATE508735T1 (de) Pulmonale verabreichung von aminoglykosiden
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
NO20061911L (no) Immunogene sammensetninger
MY144616A (en) Substituted dihydroquinazolines
ATE452900T1 (de) Impfstoff gegen das west-nile-virus
DE60023300D1 (de) Verwendung von cpg als adjuvans für hivimpstoff
BR0209145A (pt) Vacina contra varìola
BR0315437A (pt) Composição para o tratamento dos cabelos, usos da mesma e método para o tratamento dos cabelos
NO331082B1 (no) Formulering av kahalalid F, sett omfattende en slik formulering, samt rekonstituert losning derav og anvendelse av en fortynnet rekonstituert losning til fremstilling av et medikament for behandling av kreft
BR0310046A (pt) Atenuação de metapneumovìrus
AU6365301A (en) Vaccine
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
ATE410154T1 (de) Pharmazeutische zusammensetzung enthaltend 2,4- dichlorbenzylalkohol und amylmetakresol
PT1255538E (pt) Utilizacao do acido 2-metil-tiazolidin-2,4-dicarboxilico e/ou sais compativeis fisiologicamente para tratamento e/ou prevencao de cancros
BR9808226A (pt) Coronavìrus respiratório bovino como uma vacina
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
TR200002847T2 (tr) Biçim VI 5, 6-dikloro-2-(izopropilamino) -1-(beta-L-ribofüranosil) -1H-benzimidazol.
DK1227826T3 (da) Sammensætninger omfattende et ekstrakt af Perna canaliculus, methylsulfonylmethan og glucosamid samt anvendelsen heraf
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: ACAMBIS, INC. (US)

B25D Requested change of name of applicant approved

Owner name: SANOFI PASTEUR BIOLOGICS CO. (US)

B25D Requested change of name of applicant approved

Owner name: SANOFI PASTEUR BIOLOGICS, LLC (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B25A Requested transfer of rights approved

Owner name: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time